Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
November 8, 2006

Biovitrum to Improve Manufacturing Process for Protein-based Allergy Candidate

  • Biovitrum will develop and manufature Resistentia Pharmaceuticals’ new protein-based allergy drug, RES 08, for use in Phase III trials, under an agreement between the companies.

    Biovitrum will expand on the existing process for the biotechnical manufacturing of RES 08 to a standard that meets the high demands of a Phase III trial and manufacture sufficient amounts of the drug for the trial. The project will run for more than two years beginning in November.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.